CT 101
/ Sienna
- LARVOL DELTA
Home
Next
Prev
1 to 16
Of
16
Go to page
1
March 14, 2021
"@PCRonline @mirvatalasnag @sbrugaletta @Ortega_Paz @NicolaRyanI1 @CCook_MD @TomJFord @nickaram @KambisMashayek1 @chipkaminsky @aspergian1 @perc_surgeon @lewis052 @ziadalinyc @lorenzo2509 @Dr_Bitar @agtruesdell @OptimaCTO @LATAMCTO #EPeeps #CTO101 #EAPCI"
(@jedicath)
December 19, 2020
"Comments pls..🤣 I’ll start: #CTO101 @DocSavageTJU @SanChris999 @skilicmd @mmamas1973 @RhianEDavies1 @rational_doc @aspergian1 @SJcardio @Pooh_Velagapudi @Tabaza @HadyLichaaMD @KTamirisaMD @skarim01 @Almanfi_Cardio @SGuptaMD @lorenzo2509 @phillipfreeman @colum_owens"
(@mirvatalasnag)
November 08, 2020
"Would you switch to retrograde for this near flush occluded RCA #CTO101 if needed? No septals. Large tortuous LAD epicardial. If so, microcatheter of choice? @evandrofilhobr @perc_surgeon @DrAmirKaki @Babar_Basir @KAlaswadMD @Retrograde_CTO"
(@yasirakhtarMD)
November 07, 2020
"#cardiotwitter #tavi #TAVR #cto #cto101 @dr_benoy_n_shah @Stephenhenrydo1 @bartstructural @Ryvetsprog @DavidLBrownMD @nolanjimradial @adamtsao13"
(@phillipfreeman)
August 25, 2020
"How to remove a microcatheter https://t.co/0NlFDKK2o0 via @esbrilakis 5th is a 300 cm guidewire #CTO101. #cardiotwitter"
(@jedicath)
August 17, 2020
EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)
(clinicaltrials.gov)
- P1; N=6; Not yet recruiting; Sponsor: Invectys
Clinical • New P1 trial • Oncology • Solid Tumor
June 23, 2020
"How about #PCI101 similar to #CTO101? What do you think @rwyeh? https://t.co/aXO64iK5Mh"
(@willsuh76)
October 13, 2017
"Sounds great @rwyeh #IC join in? @Ravinay are you aware of @rwyeh proposed #CTO101 educational t"
(@AnastasiaSMihai)
Biosimilar • Women's Health
November 16, 2017
"#CTO101"
(@DrSheilaSahni)
Biosimilar
April 27, 2020
"FDA grants Carmell Therapeutics Expedited Review for CT-101, Bone Healing Accelerant https://t.co/UMG38No9uJ"
(@NewsFromBW)
April 16, 2020
Evaluation of the Class I histone deacetylase (HDAC) inhibitor CT-101 on fetal hemoglobin (HbF) expression in sickle progenitors and transgenic mice
(FSCDR 2020)
- No abstract available
February 15, 2020
"#CopyLeft #UpsideDownLove #CTO101 Not my image"
(@mirvatalasnag)
January 28, 2020
"@MLCTOcourse @cto101 @esbrilakis @GreggWStone @SripalBangalore @KambisMashayek1"
(@AlesqQuadros)
November 06, 2019
CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia
(clinicaltrials.gov)
- P1; N=15; Recruiting; Sponsor: Kai Lin Xu; Jun Nian Zheng
New P1 trial
November 01, 2019
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
(clinicaltrials.gov)
- P1; N=9; Not yet recruiting; Sponsor: The First Affiliated Hospital with Nanjing Medical University; Initiation date: Aug 2019 ➔ Dec 2019
Clinical • Trial initiation date
July 19, 2019
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
(clinicaltrials.gov)
- P1; N=9; Not yet recruiting; Sponsor: The First Affiliated Hospital with Nanjing Medical University
Clinical • New P1 trial
1 to 16
Of
16
Go to page
1